TetraLogic pushes Series C to $37M

Malvern, PA-based TetraLogic has added $5 million to a previously announced $32 million Series C, bringing the developer's total haul for this round to $37 million. Pfizer Ventures added the extra cash, joining a syndicate of investors led by Clarus Ventures.

TetraLogic has been gathering funding to support the development of early-stage cancer drug TL32711, a SMAC mimetic designed to neutralize the activity of an inhibitor of apoptosis proteins, which block tumor cell death. It's under investigation as a single agent in patients with hard-to-treat solid tumors and lymphoma.

"This investment is part of Pfizer Ventures' overall strategy to finance emerging companies discovering and developing promising treatments for unmet medical needs, so we're very pleased to join TetraLogic and its investors to support its efforts to advance SMAC mimetics as potential new treatments for cancer," says Elaine Jones, executive director of Pfizer Ventures.

- check out the release from TetraLogic

Suggested Articles

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea.